

Patent  
Attorney Docket No. 003300-920

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Thomas Brodin et al.

Application No.: 10/088,639

Filing Date: March 20, 2002

Title: NOVEL COMPOUNDS

Group Art Unit: 1642

Examiner: Larry Ronald Helms

Confirmation No.: 7152

**THIRD  
INFORMATION DISCLOSURE STATEMENT  
TRANSMITTAL LETTER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Enclosed is a THIRD Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.


- ☐ No additional fee for submission of an IDS is required.
- ☒ The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☒ A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \_\_\_\_\_ to Deposit Account No. 02-4800 for the fee due.
- ☒ A check in the amount of \$ 180.00 is enclosed for the fee due.
- ☐ Charge \_\_\_\_\_ to credit card. Form PTO-2038 is attached.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

By   
Deborah H. Yellin  
Registration No. 45,904

Date: April 18, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## In re Patent Application of

Thomas Brodin et al.

Application No.: 10/088,639

Filed: March 20, 2002

For: NOVEL COMPOUNDS



Group Art Unit: 1642

**Examiner: Larry Ronald Helms**

Confirmation No.: 7152

## THIRD INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**Sir:**

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted after a first Office Action on the merits but prior to the closing of prosecution, therefore under 37 C.F.R. § 1.97(c), the fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

A fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is enclosed.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

**BURNS, DOANE, SWECKER & MATHIS, L.L.P.**

Date April 18, 2005

**By:**

Deborah H. Yellin  
Registration No. 45,904

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

VA 729617.1

# **THIRD INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

**Complete if Known**

Application Number	10/088,639
Filing Date	March 20, 2002
First Named Inventor	Thomas Brodin et al.
Examiner Name	Larry Ronald Helms
Attorney Docket Number	003300-920

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Oxford Dictionary of Biochemistry and Molecular Biology, 1997, p. 165, Oxford University Press, New York.
	DOHLSTEN et al., "Monoclonal antibody-superantigen fusion proteins: Tumor-specific agents for T-cell based tumor therapy", Proc. Natl. Acad. Sci. USA, September, 1994, Vol. 91, pp. 8945-8949, Pharmacia Oncology Immunology, Lund, Sweden

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.